The Experts below are selected from a list of 39 Experts worldwide ranked by ideXlab platform

Sara M Thomasy - One of the best experts on this subject based on the ideXlab platform.

  • effects of 0 2 brimonidine and 0 2 brimonidine 0 5 timolol on intraocular pressure and pupil size in normal Equine eyes
    Equine Veterinary Journal, 2017
    Co-Authors: M. Von Zup, Mary E. Lassaline, Philip H. Kass, Paul E. Miller, Sara M Thomasy
    Abstract:

    SummaryBackground Brimonidine is an alpha 2-adrenergic agonist that decreases aqueous humor production and may increase uveoscleral outflow. It has not been evaluated in normal or Glaucomatous Equine eyes. Objectives To evaluate the IOP-lowering efficacy and safety of brimonidine, alone and in conjunction with timolol, as a treatment for Equine Glaucoma by comparing IOP in normal Equine eyes treated with brimonidine and brimonidine-timolol to control eyes. Study design A balanced crossover design with 16 horses receiving one of two treatments, brimonidine and brimonidine-timolol, during each of two 10-day study phases, was used. Four horses were randomly assigned to each of four combinations of treated eye (right or left) and drug order within the two 10-day study phases (brimonidine first or brimonidine-timolol first). Methods Pupil size and conjunctival hyperemia were assessed twice daily and IOP was measured three times daily using rebound tonometry in both eyes of 16 normal horses throughout two 10-day study periods (brimonidine and brimonidine-timolol) followed by an 18-day washout period. One eye of each horse was treated with brimonidine or brimonidine-timolol while the opposite eye was treated with balanced salt solution. Results There were no adverse effects and no significant changes in pupil size in normal Equine eyes treated with brimonidine or brimonidine-timolol. Average IOP in normal Equine eyes treated with brimonidine (25.6 mm Hg) was statistically higher than in eyes treated with brimonidine-timolol (24.6 mm Hg) or balanced salt solution (24.5 mm Hg) however IOP differences were 1 mm Hg or less and thus not clinically important. Main limitations Horses with normal eyes may not be as sensitive to IOP-lowering effects of treatment as horses with Glaucoma. Conclusions Brimonidine and briminonidine-timolol are well tolerated in normal horses but do not decrease IOP. This article is protected by copyright. All rights reserved.

  • Equine Glaucoma where are we now
    Equine Veterinary Education, 2015
    Co-Authors: Sara M Thomasy, Mary E. Lassaline
    Abstract:

    Summary The following article discusses the pathophysiology, clinical signs, diagnosis, medical treatment and surgical management of Glaucoma in the horse.

M. Von Zup - One of the best experts on this subject based on the ideXlab platform.

  • effects of 0 2 brimonidine and 0 2 brimonidine 0 5 timolol on intraocular pressure and pupil size in normal Equine eyes
    Equine Veterinary Journal, 2017
    Co-Authors: M. Von Zup, Mary E. Lassaline, Philip H. Kass, Paul E. Miller, Sara M Thomasy
    Abstract:

    SummaryBackground Brimonidine is an alpha 2-adrenergic agonist that decreases aqueous humor production and may increase uveoscleral outflow. It has not been evaluated in normal or Glaucomatous Equine eyes. Objectives To evaluate the IOP-lowering efficacy and safety of brimonidine, alone and in conjunction with timolol, as a treatment for Equine Glaucoma by comparing IOP in normal Equine eyes treated with brimonidine and brimonidine-timolol to control eyes. Study design A balanced crossover design with 16 horses receiving one of two treatments, brimonidine and brimonidine-timolol, during each of two 10-day study phases, was used. Four horses were randomly assigned to each of four combinations of treated eye (right or left) and drug order within the two 10-day study phases (brimonidine first or brimonidine-timolol first). Methods Pupil size and conjunctival hyperemia were assessed twice daily and IOP was measured three times daily using rebound tonometry in both eyes of 16 normal horses throughout two 10-day study periods (brimonidine and brimonidine-timolol) followed by an 18-day washout period. One eye of each horse was treated with brimonidine or brimonidine-timolol while the opposite eye was treated with balanced salt solution. Results There were no adverse effects and no significant changes in pupil size in normal Equine eyes treated with brimonidine or brimonidine-timolol. Average IOP in normal Equine eyes treated with brimonidine (25.6 mm Hg) was statistically higher than in eyes treated with brimonidine-timolol (24.6 mm Hg) or balanced salt solution (24.5 mm Hg) however IOP differences were 1 mm Hg or less and thus not clinically important. Main limitations Horses with normal eyes may not be as sensitive to IOP-lowering effects of treatment as horses with Glaucoma. Conclusions Brimonidine and briminonidine-timolol are well tolerated in normal horses but do not decrease IOP. This article is protected by copyright. All rights reserved.

Philip H. Kass - One of the best experts on this subject based on the ideXlab platform.

  • effects of 0 2 brimonidine and 0 2 brimonidine 0 5 timolol on intraocular pressure and pupil size in normal Equine eyes
    Equine Veterinary Journal, 2017
    Co-Authors: M. Von Zup, Mary E. Lassaline, Philip H. Kass, Paul E. Miller, Sara M Thomasy
    Abstract:

    SummaryBackground Brimonidine is an alpha 2-adrenergic agonist that decreases aqueous humor production and may increase uveoscleral outflow. It has not been evaluated in normal or Glaucomatous Equine eyes. Objectives To evaluate the IOP-lowering efficacy and safety of brimonidine, alone and in conjunction with timolol, as a treatment for Equine Glaucoma by comparing IOP in normal Equine eyes treated with brimonidine and brimonidine-timolol to control eyes. Study design A balanced crossover design with 16 horses receiving one of two treatments, brimonidine and brimonidine-timolol, during each of two 10-day study phases, was used. Four horses were randomly assigned to each of four combinations of treated eye (right or left) and drug order within the two 10-day study phases (brimonidine first or brimonidine-timolol first). Methods Pupil size and conjunctival hyperemia were assessed twice daily and IOP was measured three times daily using rebound tonometry in both eyes of 16 normal horses throughout two 10-day study periods (brimonidine and brimonidine-timolol) followed by an 18-day washout period. One eye of each horse was treated with brimonidine or brimonidine-timolol while the opposite eye was treated with balanced salt solution. Results There were no adverse effects and no significant changes in pupil size in normal Equine eyes treated with brimonidine or brimonidine-timolol. Average IOP in normal Equine eyes treated with brimonidine (25.6 mm Hg) was statistically higher than in eyes treated with brimonidine-timolol (24.6 mm Hg) or balanced salt solution (24.5 mm Hg) however IOP differences were 1 mm Hg or less and thus not clinically important. Main limitations Horses with normal eyes may not be as sensitive to IOP-lowering effects of treatment as horses with Glaucoma. Conclusions Brimonidine and briminonidine-timolol are well tolerated in normal horses but do not decrease IOP. This article is protected by copyright. All rights reserved.

Paul E. Miller - One of the best experts on this subject based on the ideXlab platform.

  • effects of 0 2 brimonidine and 0 2 brimonidine 0 5 timolol on intraocular pressure and pupil size in normal Equine eyes
    Equine Veterinary Journal, 2017
    Co-Authors: M. Von Zup, Mary E. Lassaline, Philip H. Kass, Paul E. Miller, Sara M Thomasy
    Abstract:

    SummaryBackground Brimonidine is an alpha 2-adrenergic agonist that decreases aqueous humor production and may increase uveoscleral outflow. It has not been evaluated in normal or Glaucomatous Equine eyes. Objectives To evaluate the IOP-lowering efficacy and safety of brimonidine, alone and in conjunction with timolol, as a treatment for Equine Glaucoma by comparing IOP in normal Equine eyes treated with brimonidine and brimonidine-timolol to control eyes. Study design A balanced crossover design with 16 horses receiving one of two treatments, brimonidine and brimonidine-timolol, during each of two 10-day study phases, was used. Four horses were randomly assigned to each of four combinations of treated eye (right or left) and drug order within the two 10-day study phases (brimonidine first or brimonidine-timolol first). Methods Pupil size and conjunctival hyperemia were assessed twice daily and IOP was measured three times daily using rebound tonometry in both eyes of 16 normal horses throughout two 10-day study periods (brimonidine and brimonidine-timolol) followed by an 18-day washout period. One eye of each horse was treated with brimonidine or brimonidine-timolol while the opposite eye was treated with balanced salt solution. Results There were no adverse effects and no significant changes in pupil size in normal Equine eyes treated with brimonidine or brimonidine-timolol. Average IOP in normal Equine eyes treated with brimonidine (25.6 mm Hg) was statistically higher than in eyes treated with brimonidine-timolol (24.6 mm Hg) or balanced salt solution (24.5 mm Hg) however IOP differences were 1 mm Hg or less and thus not clinically important. Main limitations Horses with normal eyes may not be as sensitive to IOP-lowering effects of treatment as horses with Glaucoma. Conclusions Brimonidine and briminonidine-timolol are well tolerated in normal horses but do not decrease IOP. This article is protected by copyright. All rights reserved.

Mary E. Lassaline - One of the best experts on this subject based on the ideXlab platform.

  • effects of 0 2 brimonidine and 0 2 brimonidine 0 5 timolol on intraocular pressure and pupil size in normal Equine eyes
    Equine Veterinary Journal, 2017
    Co-Authors: M. Von Zup, Mary E. Lassaline, Philip H. Kass, Paul E. Miller, Sara M Thomasy
    Abstract:

    SummaryBackground Brimonidine is an alpha 2-adrenergic agonist that decreases aqueous humor production and may increase uveoscleral outflow. It has not been evaluated in normal or Glaucomatous Equine eyes. Objectives To evaluate the IOP-lowering efficacy and safety of brimonidine, alone and in conjunction with timolol, as a treatment for Equine Glaucoma by comparing IOP in normal Equine eyes treated with brimonidine and brimonidine-timolol to control eyes. Study design A balanced crossover design with 16 horses receiving one of two treatments, brimonidine and brimonidine-timolol, during each of two 10-day study phases, was used. Four horses were randomly assigned to each of four combinations of treated eye (right or left) and drug order within the two 10-day study phases (brimonidine first or brimonidine-timolol first). Methods Pupil size and conjunctival hyperemia were assessed twice daily and IOP was measured three times daily using rebound tonometry in both eyes of 16 normal horses throughout two 10-day study periods (brimonidine and brimonidine-timolol) followed by an 18-day washout period. One eye of each horse was treated with brimonidine or brimonidine-timolol while the opposite eye was treated with balanced salt solution. Results There were no adverse effects and no significant changes in pupil size in normal Equine eyes treated with brimonidine or brimonidine-timolol. Average IOP in normal Equine eyes treated with brimonidine (25.6 mm Hg) was statistically higher than in eyes treated with brimonidine-timolol (24.6 mm Hg) or balanced salt solution (24.5 mm Hg) however IOP differences were 1 mm Hg or less and thus not clinically important. Main limitations Horses with normal eyes may not be as sensitive to IOP-lowering effects of treatment as horses with Glaucoma. Conclusions Brimonidine and briminonidine-timolol are well tolerated in normal horses but do not decrease IOP. This article is protected by copyright. All rights reserved.

  • Equine Glaucoma where are we now
    Equine Veterinary Education, 2015
    Co-Authors: Sara M Thomasy, Mary E. Lassaline
    Abstract:

    Summary The following article discusses the pathophysiology, clinical signs, diagnosis, medical treatment and surgical management of Glaucoma in the horse.

  • a promising surgical approach to Equine Glaucoma
    Equine Veterinary Education, 2015
    Co-Authors: Mary E. Lassaline
    Abstract:

    Summary The preceding case report by Wilson et al. (2015) describes the surgical placement of a Baerveldt Glaucoma shunt in a Glaucomatous Equine eye that had been refractory to aggressive medical and repeated surgical therapies yet maintained functional vision. Shunt placement surgery successfully maintained vision and intraocular pressure in the normal range in the affected eye. This is the first report of long-term successful Glaucoma filtration surgery in a horse. Glaucoma shunt placement shows promise for maintaining vision and comfort in Equine eyes affected with Glaucoma. There is much to be learned in terms of the most appropriate implant type for the Equine eye, the risk of complications such as ocular hypotony or tube fibrosis, and the utility of combination therapy with transcleral cyclophotocoagulation and implant placement, but with the report of one case in which gonioimplant placement has been associated with intraocular pressure control for over one year, further investigations appear warranted. This case provides a glimmer of hope for long-term treatment of a painful, blinding disease that has traditionally carried a poor prognosis in horses.